No Data
No Data
No Data
No Data
No Data
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
GlobeNewswireMay 7 20:00
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance
BioAtla (BCAB) said Monday its investigational new drug application to assess BA3361 antibody drug conjugate to treat multiple tumor types has been cleared by the US Food and Drug Administration. The
MT NewswiresMay 6 21:14
BioAtla Announces FDA Clearance Of Investigational New Drug Application For BA3361
BioAtla Announces FDA Clearance Of Investigational New Drug Application For BA3361
BenzingaMay 6 20:07
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
BenzingaMay 3 00:31
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
GlobeNewswireApr 25 04:35
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability
TipRanksApr 11 07:05
No Data
No Data